Literature DB >> 33380882

Abstracts submitted to the Cell Therapy Transplant Canada 2020 Annual Conference: Cell Therapy Transplant Canada.

.   

Abstract

Year:  2020        PMID: 33380882      PMCID: PMC7755441          DOI: 10.3747/co.27.7151

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


× No keyword cloud information.
  5 in total

1.  An objective flow cytometry method to rapidly determine cord blood potency in cryopreserved units.

Authors:  Carl Simard; Guillaume Bonnaure; Diane Fournier; Sonia Néron
Journal:  Transfusion       Date:  2019-02-25       Impact factor: 3.157

2.  Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.

Authors:  Christian Grommes; Alessandro Pastore; Nicolaos Palaskas; Sarah S Tang; Carl Campos; Derrek Schartz; Paolo Codega; Donna Nichol; Owen Clark; Wan-Ying Hsieh; Dan Rohle; Marc Rosenblum; Agnes Viale; Viviane S Tabar; Cameron W Brennan; Igor T Gavrilovic; Thomas J Kaley; Craig P Nolan; Antonio Omuro; Elena Pentsova; Alissa A Thomas; Elina Tsyvkin; Ariela Noy; M Lia Palomba; Paul Hamlin; Craig S Sauter; Craig H Moskowitz; Julia Wolfe; Ahmet Dogan; Minhee Won; Jon Glass; Scott Peak; Enrico C Lallana; Vaios Hatzoglou; Anne S Reiner; Philip H Gutin; Jason T Huse; Katherine S Panageas; Thomas G Graeber; Nikolaus Schultz; Lisa M DeAngelis; Ingo K Mellinghoff
Journal:  Cancer Discov       Date:  2017-06-15       Impact factor: 39.397

Review 3.  Introduction of novel agents in the treatment of primary CNS lymphoma.

Authors:  Christian Grommes; Lakshmi Nayak; Han W Tun; Tracy T Batchelor
Journal:  Neuro Oncol       Date:  2019-02-19       Impact factor: 12.300

4.  Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.

Authors:  Michail S Lionakis; Kieron Dunleavy; Mark Roschewski; Brigitte C Widemann; John A Butman; Roland Schmitz; Yandan Yang; Diane E Cole; Christopher Melani; Christine S Higham; Jigar V Desai; Michele Ceribelli; Lu Chen; Craig J Thomas; Richard F Little; Juan Gea-Banacloche; Sucharita Bhaumik; Maryalice Stetler-Stevenson; Stefania Pittaluga; Elaine S Jaffe; John Heiss; Nicole Lucas; Seth M Steinberg; Louis M Staudt; Wyndham H Wilson
Journal:  Cancer Cell       Date:  2017-05-25       Impact factor: 31.743

5.  Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network.

Authors:  C Soussain; S Choquet; M Blonski; D Leclercq; C Houillier; K Rezai; F Bijou; R Houot; E Boyle; R Gressin; E Nicolas-Virelizier; M Barrie; C Moluçon-Chabrot; M L Lelez; A Clavert; S Coisy; S Leruez; V Touitou; N Cassoux; M Daniau; M Ertault de la Bretonnière; A El Yamani; H Ghesquières; K Hoang-Xuan
Journal:  Eur J Cancer       Date:  2019-07-03       Impact factor: 9.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.